Innovus Pharmaceuticals Competitors

Nexien BioPharma (OTCMKTS:NXEN) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Earnings & Valuation

This table compares Nexien BioPharma and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Nexien BioPharma has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Risk and Volatility

Nexien BioPharma has a beta of -701.47, meaning that its stock price is 70,247% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 30.6% of Nexien BioPharma shares are owned by company insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Nexien BioPharma and Innovus Pharmaceuticals, as provided by MarketBeat.

Profitability

This table compares Nexien BioPharma and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Innovus Pharmaceuticals beats Nexien BioPharma on 5 of the 8 factors compared between the two stocks.

Tower One Wireless (OTCMKTS:TOWTF) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Tower One Wireless has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tower One Wireless and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Tower One Wireless has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Tower One Wireless and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tower One Wireless and Innovus Pharmaceuticals, as reported by MarketBeat.

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500.

Earnings and Valuation

This table compares Acerus Pharmaceuticals and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Innovus Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals.

Profitability

This table compares Acerus Pharmaceuticals and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Comparatively, 10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Acerus Pharmaceuticals and Innovus Pharmaceuticals, as provided by MarketBeat.com.

Summary

Innovus Pharmaceuticals beats Acerus Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Innovus Pharmaceuticals and Peak Pharmaceuticals, as provided by MarketBeat.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Peak Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Profitability

This table compares Innovus Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innovus Pharmaceuticals beats Peak Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and GlobeImmune (OTCMKTS:GBIM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, GlobeImmune has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Innovus Pharmaceuticals and GlobeImmune, as provided by MarketBeat.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and GlobeImmune's revenue, earnings per share (EPS) and valuation.

GlobeImmune has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Profitability

This table compares Innovus Pharmaceuticals and GlobeImmune's net margins, return on equity and return on assets.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 23.5% of GlobeImmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

GlobeImmune beats Innovus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Williston (OTCMKTS:WHCA) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Williston and Innovus Pharmaceuticals, as provided by MarketBeat.com.

Volatility & Risk

Williston has a beta of -1.09, meaning that its share price is 209% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Williston and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Williston and Innovus Pharmaceuticals' revenue, earnings per share and valuation.

Williston has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Summary

Innovus Pharmaceuticals beats Williston on 4 of the 7 factors compared between the two stocks.